骨髓增殖性肿瘤患者感染COVID-19后突然停用芦可替尼与高死亡率相关
该研究纳入2020年2月至6月诊断的175例骨髓增殖性肿瘤(MPN)合并COVID-19患者,中位随访50天,骨髓纤维化(MF)患者死亡率达48%。单因素分析显示死亡与年龄、男性、淋巴细胞减少、呼吸支持需求、合并症及MF诊断相关;多因素分析未发现芦可替尼本身影响死亡率,但45例中11例停药者死亡风险增加,倾向性评分匹配分析亦证实。
要点
- MPN合并COVID-19患者死亡率高,MF患者达48%。
- 死亡风险与年龄、男性、淋巴细胞减少、呼吸支持、合并症及MF相关。
- 芦可替尼本身未增加死亡风险,但诊断COVID-19时突然停药者死亡风险增加。
核心结论
- MPN患者感染COVID-19期间死亡风险高,尤其MF患者和诊断时停用芦可替尼者。
研究设计与样本
- 回顾性队列研究,纳入2020年2月至6月诊断的175例MPN合并COVID-19患者,中位随访50天。
主要发现
- MF患者死亡率为48%。
- 单因素分析显示死亡与年龄、男性、淋巴细胞减少、呼吸支持需求、合并症及MF诊断显著相关,与ET、PV及pre-PMF无关联。
- 死亡患者中芦可替尼使用比例显著高于存活者(p=0.006)。
- 多因素分析未发现芦可替尼单药对死亡率有影响,但45例中11例停药者死亡风险增加,倾向性评分匹配分析证实。
临床怎么用
- 对MPN合并COVID-19患者应警惕高死亡风险,尤其MF患者。
- 诊断COVID-19时不应突然停用芦可替尼,需权衡停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.
引用
- Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021. PMID: 33414483. doi:10.1038/s41375-020-01107-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。